{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:20:45Z","timestamp":1774538445708,"version":"3.50.1"},"reference-count":120,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.humimm.2024.110836","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T10:29:30Z","timestamp":1720434570000},"page":"110836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Generation of immune cells from induced pluripotent stem cells (iPSCs): Their potential for adoptive cell therapy"],"prefix":"10.1016","volume":"85","author":[{"given":"Mahsa","family":"Gheitasi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1562-3257","authenticated-orcid":false,"given":"Sepeher","family":"Safdel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sananda","family":"Kumar Patra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3112-676X","authenticated-orcid":false,"given":"Raziyeh","family":"Zandvakili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Nemati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5833-7912","authenticated-orcid":false,"given":"Bhaskar","family":"Saha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8180-0602","authenticated-orcid":false,"given":"Abdollah","family":"Jafarzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humimm.2024.110836_b0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13223-018-0278-1","article-title":"An introduction to immunology and immunopathology","volume":"14","author":"Marshall","year":"2018","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0010","first-page":"61","article-title":"Primary immunodeficiency. Allergy Asthma","volume":"14","author":"McCusker","year":"2018","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.anai.2021.08.413","article-title":"Secondary immunodeficiencies: an overview","volume":"127","author":"Tuano","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0020","first-page":"231","article-title":"Chapter 9 \u2013 an overview of reprogramming approaches to derive integration-free induced pluripotent stem cells for prospective biomedical applications","volume":"vol. 5","author":"Dey","year":"2021"},{"key":"10.1016\/j.humimm.2024.110836_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2024.03.483","article-title":"Neutrophil generation from hematopoietic progenitor cells and induced pluripotent stem cells (iPSCs): potential applications","author":"Jafarzadeh","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.humimm.2024.110836_b0030","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1139\/O09-188","article-title":"Derivation of human embryonic stem cell lines after blastocyst microsurgery","volume":"88","author":"Meng","year":"2010","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/j.humimm.2024.110836_b0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.blre.2005.01.005","article-title":"Therapeutic potential of embryonic stem cells","volume":"19","author":"Lerou","year":"2005","journal-title":"Blood Rev."},{"key":"10.1016\/j.humimm.2024.110836_b0040","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1210\/er.2008-0031","article-title":"Ethical issues in stem cell research","volume":"30","author":"Lo","year":"2009","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.humimm.2024.110836_b0045","first-page":"29","article-title":"Chapter 2 \u2013 auxiliary pluripotency-associated genes and their contributions in the generation of induced pluripotent stem cells","volume":"vol. 12","author":"Dey","year":"2022"},{"key":"10.1016\/j.humimm.2024.110836_b0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-4939-1619-1_5","article-title":"Generation of induced pluripotent stem cells","volume":"1226","author":"Deyle","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.humimm.2024.110836_b0055","article-title":"Engineering induced pluripotent stem cells for cancer immunotherapy","volume":"14","author":"Zhou","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.humimm.2024.110836_b0060","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41576-019-0100-z","article-title":"Induced pluripotent stem cells in disease modelling and drug discovery","volume":"20","author":"Rowe","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.humimm.2024.110836_b0065","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrd.2016.245","article-title":"Induced pluripotent stem cell technology: a decade of progress","volume":"16","author":"Shi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.humimm.2024.110836_b0070","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s12015-021-10262-3","article-title":"Review of the current trends in clinical trials involving induced pluripotent stem cells","volume":"18","author":"Kim","year":"2022","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.humimm.2024.110836_b0075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/cmi.2013.62","article-title":"Induced pluripotent stem cell (iPSCs) and their application in immunotherapy","volume":"11","author":"Jiang","year":"2014","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0080","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.humimm.2024.110836_b0085","unstructured":"B. Immacolata, R. Veronica, N. Daria, C. Clotilde, M. Franca Di, Non-integrating methods to produce induced pluripotent stem cells for regenerative medicine: an overview, in: S.H. Ziyad, Y.A. Ibrokhim, B. Abdelwahed, (Eds.), Biomechanics and Functional Tissue Engineering, Rijeka, IntechOpen, 2020, p Ch. 5."},{"key":"10.1016\/j.humimm.2024.110836_b0090","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.gene.2018.11.069","article-title":"An insight into non-integrative gene delivery approaches to generate transgene-free induced pluripotent stem cells","volume":"686","author":"Haridhasapavalan","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.humimm.2024.110836_b0095","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.humimm.2024.110836_b0100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nature06534","article-title":"Reprogramming of human somatic cells to pluripotency with defined factors","volume":"451","author":"Park","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.humimm.2024.110836_b0105","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1126\/science.1151526","article-title":"Induced pluripotent stem cell lines derived from human somatic cells","volume":"318","author":"Yu","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.humimm.2024.110836_b0110","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/cr.2010.142","article-title":"Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules","volume":"21","author":"Li","year":"2011","journal-title":"Cell Res."},{"key":"10.1016\/j.humimm.2024.110836_b0115","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1007\/s12015-021-10200-3","article-title":"An overview on promising somatic cell sources utilized for the efficient generation of induced pluripotent stem cells","volume":"17","author":"Ray","year":"2021","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.humimm.2024.110836_b0120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.stem.2010.06.004","article-title":"Reprogramming of T cells from human peripheral blood","volume":"7","author":"Loh","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.humimm.2024.110836_b0125","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-1-0716-1084-8_9","article-title":"Generation of human iPSCs by episomal reprogramming of skin fibroblasts and peripheral blood mononuclear cells","volume":"2239","author":"Febbraro","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.humimm.2024.110836_b0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2012.12.006","article-title":"Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells","volume":"12","author":"Vizcardo","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.humimm.2024.110836_b0135","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/leu.2015.294","article-title":"Reprogramming human B cells into induced pluripotent stem cells and its enhancement by C\/EBP\u03b1","volume":"30","author":"Bueno","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.humimm.2024.110836_b0140","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/cbin.11854","article-title":"Biology of macrophage fate decision: Implication in inflammatory disorders","volume":"46","author":"Yadav","year":"2022","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.humimm.2024.110836_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118102","article-title":"Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions","volume":"257","author":"Jafarzadeh","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.humimm.2024.110836_b0150","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Shapouri-Moghaddam","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.humimm.2024.110836_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232416087","article-title":"iPSC-derived macrophages: the differentiation protocol affects cell immune characteristics and differentiation trajectories","volume":"23","author":"Klepikova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.humimm.2024.110836_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.640703","article-title":"Macrophages derived from human induced pluripotent stem cells: the diversity of protocols, future prospects, and outstanding questions","volume":"9","author":"Lyadova","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.humimm.2024.110836_b0165","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.humimm.2024.110836_b0170","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.humimm.2024.110836_b0175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4939-7837-3_2","article-title":"A simple multistep protocol for differentiating human induced pluripotent stem cells into functional macrophages","volume":"1784","author":"Mukherjee","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.humimm.2024.110836_b0180","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.stemcr.2019.05.003","article-title":"Differentiation and functional comparison of monocytes and macrophages from hiPSCs with peripheral blood derivatives","volume":"12","author":"Cao","year":"2019","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.humimm.2024.110836_b0185","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0190","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1053\/j.seminhematol.2020.10.004","article-title":"NK cells as adoptive cellular therapy for hematological malignancies: advantages and hurdles","volume":"57","author":"Caruso","year":"2020","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.humimm.2024.110836_b0195","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/imr.12793","article-title":"Cellular therapy: adoptive immunotherapy with expanded natural killer cells","volume":"290","author":"Lee","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.humimm.2024.110836_b0200","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jcyt.2022.12.003","article-title":"The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer","volume":"25","author":"Klingemann","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.humimm.2024.110836_b0205","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/eji.201747134","article-title":"NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHD","volume":"48","author":"Chan","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0210","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.humimm.2024.110836_b0215","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood.V122.21.896.896","article-title":"Functional chimeric antigen receptor-expressing natural killer cells derived from human pluripotent stem cells","volume":"122","author":"Hermanson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.110836_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.841107","article-title":"iPSC-derived natural killer cell therapies \u2013 expansion and targeting","volume":"13","author":"Goldenson","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0225","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1128\/JVI.01774-10","article-title":"Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms","volume":"85","author":"Ni","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.humimm.2024.110836_b0230","first-page":"12","article-title":"iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy","author":"Cichocki","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.humimm.2024.110836_b0235","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.110836_b0240","first-page":"3451807","article-title":"Induced pluripotent stem cell as a new source for cancer immunotherapy","volume":"2016","author":"Rami","year":"2016","journal-title":"Genet Res Int"},{"key":"10.1016\/j.humimm.2024.110836_b0245","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640672","article-title":"Natural killer cells generated from human induced pluripotent stem cells mature to CD56(bright)CD16(+)NKp80(+\/-)in-vitro and express KIR2DL2\/DL3 and KIR3DL1","volume":"12","author":"Euchner","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0250","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.humimm.2024.110836_b0255","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-4939-9728-2_12","article-title":"An improved method to produce clinical-scale natural killer cells from human pluripotent stem cells","volume":"2048","author":"Zhu","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.humimm.2024.110836_b0260","first-page":"e50337","article-title":"Development, expansion, and in vivo monitoring of human NK cells from human embryonic stem cells (hESCs) and and induced pluripotent stem cells (iPSCs)","author":"Bock","year":"2013","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.humimm.2024.110836_b0265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.561553","article-title":"Umbilical cord blood and iPSC-derived natural killer cells demonstrate key differences in cytotoxic activity and KIR profiles","volume":"11","author":"Goldenson","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0270","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/stem.2230","article-title":"Induced pluripotent stem cell-derived natural killer cells for treatment of ovarian cancer","volume":"34","author":"Hermanson","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.humimm.2024.110836_b0275","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13287-020-01741-4","article-title":"Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies","volume":"11","author":"Shankar","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.humimm.2024.110836_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115123","article-title":"IPSC-derived CAR-NK cells for cancer immunotherapy","volume":"165","author":"Lin","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.humimm.2024.110836_b0285","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1097\/QAD.0000000000001645","article-title":"Natural killer cells in HIV-1 infection and therapy","volume":"31","author":"Mikulak","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.humimm.2024.110836_b0290","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00441-010-1023-3","article-title":"Invariant natural killer T cells: bridging innate and adaptive immunity","volume":"343","author":"Van Kaer","year":"2011","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.humimm.2024.110836_b0295","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/cr.2008.85","article-title":"NKT cells in HIV-1 infection","volume":"18","author":"Li","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.humimm.2024.110836_b0300","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.stemcr.2016.01.005","article-title":"Cellular adjuvant properties, direct cytotoxicity of re-differentiated V\u03b124 invariant NKT-like cells from human induced pluripotent stem cells","volume":"6","author":"Kitayama","year":"2016","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.humimm.2024.110836_b0305","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.2277","article-title":"Efficient production of functional human NKT cells from induced pluripotent stem cells \u2013 reprogramming of human V\u03b124(+)iNKT cells","volume":"7","author":"Yamada","year":"2017","journal-title":"Bio Protoc"},{"key":"10.1016\/j.humimm.2024.110836_b0310","first-page":"A305","article-title":"290 A novel iPSC-derived CAR-invariant natural killer T (iNKT) cell therapy platform for hematologic malignancies and solid tumors","volume":"10","author":"Urakami","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.humimm.2024.110836_b0315","first-page":"1411","article-title":"Application of iPS cell-derived NKT cells to cancer immunotherapy","volume":"47","author":"Motohashi","year":"2020","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.humimm.2024.110836_b0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.ircmb.2019.07.004","article-title":"Dendritic cell subsets and locations","volume":"348","author":"Balan","year":"2019","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.humimm.2024.110836_b0325","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3389\/fimmu.2013.00192","article-title":"Tumor-altered dendritic cell function: implications for anti-tumor immunity","volume":"4","author":"Hargadon","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0330","doi-asserted-by":"crossref","first-page":"565","DOI":"10.18609\/cgti.2019.062","article-title":"Immunotherapy with iPSC-derived dendritic cells brings a new perspective to an old debate: autologous versus allogeneic?","volume":"5","author":"Fairchild","year":"2019","journal-title":"Cell Gene Ther. Insights"},{"key":"10.1016\/j.humimm.2024.110836_b0335","first-page":"9","article-title":"In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models","author":"Oba","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.humimm.2024.110836_b0340","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/stem.3095","article-title":"Induced pluripotent stem cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy","volume":"38","author":"Horton","year":"2020","journal-title":"Stem Cells"},{"key":"10.1016\/j.humimm.2024.110836_b0345","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/eji.202149550","article-title":"Dendritic cells generated from induced pluripotent stem cells and by direct reprogramming of somatic cells","volume":"52","author":"Flosdorf","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0350","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01935","article-title":"Directed differentiation of human induced pluripotent stem cells into dendritic cells displaying tolerogenic properties and resembling the CD141+ subset","volume":"8","author":"Sachamitr","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0355","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/gt.2011.177","article-title":"Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells","volume":"19","author":"Silk","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.humimm.2024.110836_b0360","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/gt.2011.22","article-title":"Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy","volume":"18","author":"Senju","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.humimm.2024.110836_b0365","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.2419","article-title":"Differentiation of human induced pluripotent stem cells (iPS cells) and embryonic stem cells (ES Cells) into dendritic cell (DC) subsets","volume":"7","author":"Sontag","year":"2017","journal-title":"Bio Protoc"},{"key":"10.1016\/j.humimm.2024.110836_b0370","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/stem.2565","article-title":"Modelling IRF8 deficient human hematopoiesis and dendritic cell development with engineered iPS cells","volume":"35","author":"Sontag","year":"2017","journal-title":"Stem Cells"},{"key":"10.1016\/j.humimm.2024.110836_b0375","article-title":"Human DC3 antigen presenting dendritic cells from induced pluripotent stem cells","author":"Satoh","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.humimm.2024.110836_b0380","first-page":"10","article-title":"Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling","author":"Makino","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.humimm.2024.110836_b0385","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3389\/fimmu.2012.00274","article-title":"Regulatory dendritic cells: there is more than just immune activation","volume":"3","author":"Schmidt","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0390","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.trre.2019.05.001","article-title":"Regulatory dendritic cells for human organ transplantation","volume":"33","author":"Thomson","year":"2019","journal-title":"Transplant. Rev. (Orlando)"},{"key":"10.1016\/j.humimm.2024.110836_b0395","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.smim.2011.06.007","article-title":"Tolerogenic dendritic cells and their role in transplantation","volume":"23","author":"Ezzelarab","year":"2011","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0400","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.imlet.2013.11.016","article-title":"Regulatory dendritic cell therapy: from rodents to clinical application","volume":"161","author":"Ra\u00efch-Regu\u00e9","year":"2014","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.humimm.2024.110836_b0405","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1038\/srep03979","article-title":"Generation and characterization of regulatory dendritic cells derived from murine induced pluripotent stem cells","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.humimm.2024.110836_b0410","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8873383","article-title":"HLA DR genome editing with TALENs in human iPSCs produced immune-tolerant dendritic cells","volume":"2021","author":"Kwon","year":"2021","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.humimm.2024.110836_b0415","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.humimm.2024.110836_b0420","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.semcancer.2007.06.008","article-title":"Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors","volume":"17","author":"Mescher","year":"2007","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.humimm.2024.110836_b0425","first-page":"24","article-title":"Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells","volume":"7","author":"Ueda","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.humimm.2024.110836_b0430","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood.2023020528","article-title":"Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8\u03b1\u03b2+ T cells targeting multiple myeloma","volume":"143","author":"Bae","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.110836_b0435","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1158\/0008-5472.CAN-16-1149","article-title":"Regeneration of CD8\u03b1\u03b2 T cells from T-cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity","volume":"76","author":"Maeda","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.humimm.2024.110836_b0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.100998","article-title":"Cytotoxic T lymphocytes regenerated from ips cells have therapeutic efficacy in a patient-derived xenograft solid tumor model","volume":"23","author":"Kashima","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.humimm.2024.110836_b0445","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3727\/096368916X690467","article-title":"Melanoma immunotherapy in mice using genetically engineered pluripotent stem cells","volume":"25","author":"Haque","year":"2016","journal-title":"Cell Transplant."},{"key":"10.1016\/j.humimm.2024.110836_b0450","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-4939-8885-3_3","article-title":"Generation of tumor antigen-specific cytotoxic T lymphocytes from pluripotent stem cells","volume":"1884","author":"Chen","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.humimm.2024.110836_b0455","article-title":"Development and characterization of naive single-type tumor antigen-specific CD8(+) T lymphocytes from murine pluripotent stem cells","volume":"6","author":"Lei","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.humimm.2024.110836_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2020.100264","article-title":"An optimized protocol for the generation of HBV viral antigen-specific T lymphocytes from pluripotent stem cells","volume":"2","author":"Haque","year":"2021","journal-title":"STAR Protoc"},{"key":"10.1016\/j.humimm.2024.110836_b0465","doi-asserted-by":"crossref","DOI":"10.3791\/60043-v","article-title":"Stem cell-derived viral ag-specific T lymphocytes suppress HBV replication in mice","author":"Xiong","year":"2019","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.humimm.2024.110836_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101333","article-title":"Stem cell-derived viral antigen-specific T cells suppress HBV replication through production of IFN-\u03b3 and TNF-\u237a","volume":"23","author":"Haque","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.humimm.2024.110836_b0475","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1016\/j.ymthe.2020.07.004","article-title":"Sustainable tumor-suppressive effect of iPSC-derived rejuvenated T cells targeting cervical cancers","volume":"28","author":"Honda","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.humimm.2024.110836_b0480","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.micpath.2018.01.040","article-title":"T cell subsets play an important role in the determination of the clinical outcome of Helicobacter pylori infection","volume":"116","author":"Jafarzadeh","year":"2018","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.humimm.2024.110836_b0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellimm.2009.09.005","article-title":"T lineage differentiation from induced pluripotent stem cells","volume":"260","author":"Lei","year":"2009","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0490","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.4237","article-title":"Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids","volume":"14","author":"Seet","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.humimm.2024.110836_b0495","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.stem.2018.12.011","article-title":"Organoid-induced differentiation of conventional T cells from human pluripotent stem cells","volume":"24","author":"Montel-Hagen","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.humimm.2024.110836_b0500","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.759558","article-title":"Advances in adoptive cell therapy using induced pluripotent stem cell-derived T cells","volume":"12","author":"Netsrithong","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0505","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1182\/blood.V126.23.3424.3424","article-title":"Generation of BCR-ABL reactive CD4+ T helper cells by reprograming and redifferentiation","volume":"126","author":"Ueda","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.110836_b0510","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2035117","article-title":"Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders \u2013 advances and challenges","volume":"18","author":"Goswami","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.humimm.2024.110836_b0515","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4049\/jimmunol.1200633","article-title":"Programming of regulatory T cells from pluripotent stem cells and prevention of autoimmunity","volume":"189","author":"Haque","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0520","doi-asserted-by":"crossref","DOI":"10.3791\/54720-v","article-title":"Development of stem cell-derived antigen-specific regulatory T cells against autoimmunity","author":"Haque","year":"2016","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.humimm.2024.110836_b0525","article-title":"\u03b3\u03b4 T cells and their roles in immunotherapy: a narrative review","volume":"7","author":"Chen","year":"2021","journal-title":"Ann. Blood"},{"key":"10.1016\/j.humimm.2024.110836_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.174803","article-title":"Gamma delta (\u03b3\u03b4) T cells in cancer immunotherapy; where it comes from, where it will go?","volume":"919","author":"Deng","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.humimm.2024.110836_b0535","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12943-023-01722-0","article-title":"Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment","volume":"22","author":"Gao","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.humimm.2024.110836_b0540","doi-asserted-by":"crossref","DOI":"10.3791\/62622-v","article-title":"Expansion and enrichment of gamma-delta (\u03b3\u03b4) T cells from apheresed human product","author":"Landin","year":"2021","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.humimm.2024.110836_b0545","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/CJI.0000000000000445","article-title":"Large scale ex vivo expansion of \u03b3\u03b4 T cells using artificial antigen-presenting cells","volume":"46","author":"Boucher","year":"2023","journal-title":"J. Immunother."},{"key":"10.1016\/j.humimm.2024.110836_b0550","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/sctm.17-0021","article-title":"The generation of human \u03b3\u03b4T cell-derived induced pluripotent stem cells from whole peripheral blood mononuclear cell culture","volume":"7","author":"Watanabe","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.humimm.2024.110836_b0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216815","article-title":"Derivation of mimetic \u03b3\u03b4 T cells endowed with cancer recognition receptors from reprogrammed \u03b3\u03b4 T cell","volume":"14","author":"Zeng","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.humimm.2024.110836_b0560","first-page":"60","article-title":"Primary immunodeficiencies of the B lymphocyte","volume":"3","author":"Moise","year":"2010","journal-title":"J. Med. Life"},{"key":"10.1016\/j.humimm.2024.110836_b0565","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood-2010-08-299941","article-title":"Human induced pluripotent stem cells are capable of B-cell lymphopoiesis","volume":"117","author":"Carpenter","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.110836_b0570","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1089\/scd.2014.0318","article-title":"Human induced pluripotent stem cell-derived B lymphocytes express sIgM and can be generated via a hemogenic endothelium intermediate","volume":"24","author":"French","year":"2015","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.humimm.2024.110836_b0575","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/cmi.2013.60","article-title":"The immunogenicity of cells derived from induced pluripotent stem cells","volume":"11","author":"Fu","year":"2014","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0580","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3389\/fimmu.2017.00645","article-title":"The immunogenicity and immune tolerance of pluripotent stem cell derivatives","volume":"8","author":"Liu","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.110836_b0585","article-title":"Low immunogenicity of neural progenitor cells differentiated from induced pluripotent stem cells derived from less immunogenic somatic cells","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.humimm.2024.110836_b0590","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","article-title":"Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients","volume":"37","author":"Deuse","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.humimm.2024.110836_b0595","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12929-019-0578-x","article-title":"Human iPSC banking: barriers and opportunities","volume":"26","author":"Huang","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.humimm.2024.110836_b0600","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.scr.2017.03.002","article-title":"Rapid establishment of the European Bank for induced Pluripotent Stem Cells (EBiSC) \u2013 the Hot Start experience","volume":"20","author":"De Sousa","year":"2017","journal-title":"Stem Cell Res."}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019888592400096X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019888592400096X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T09:38:06Z","timestamp":1726220286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019888592400096X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":120,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S019888592400096X"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2024.110836","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generation of immune cells from induced pluripotent stem cells (iPSCs): Their potential for adoptive cell therapy","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2024.110836","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110836"}}